Tag:
Alexza Pharmaceuticals
Latest Headlines
Latest Headlines
FDA whacks Alexza Pharma with CRL for Adasuve
The FDA shot down the company's latest application because of manufacturing deficiencies related to the device used to take the inhaled antipsychotic drug, the company revealed last night.
Alexza layoffs looming
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,
Alexza readies "significant" layoffs, brings in Lazard to review asset sale
Just days after eking out an FDA expert panel vote in favor of its inhaled antipsychotic Adasuve, Alexza Pharma ( $ALXA ) has brought in Lazard to investigate the possible sale of assets as it prepares
Alexza shares spike after antipsychotic wins weak embrace from FDA panel
Alexza Pharma ( $ALXA ) just barely managed to clear one of the big hurdles that threatened to once again block its marathon effort at winning an FDA approval of the inhaled antipsychotic treatment
Alexza Pharma shares tank on FDA's safety concerns about Adasuve
Investors appeared to get worried after FDA staffers cited worries about lung safety issues with Alexza Pharmaceuticals' ( $ALXA ) inhaled anti-agitation drug Adasuve. Shares of the developers stock
Alexza lands European partner for stymied agitation therapy
With the FDA blocking an approval for Alexza's ( $ALXA ) anti-agitation treatment Adasuve (AZ-004), the U.S. biotech has forged ahead with a European pact that brings a $10 million upfront payment with
Alexza shares plunge after it offers new timetable for AZ-004
Alexza Pharmaceuticals ( $ALXA ) says it has had a chance to sit down with the FDA to discuss its stalled application for AZ-004, an inhaled, fast-acting treatment for the management of schizophrenia
Alexza shares plunge as FDA refuses to approve AZ-004
Worried by early-stage safety data highlighting troubling respiratory problems for patients taking an inhaled, fast-acting therapy to manage schizophrenia and bipolar disorder, the FDA has decided to
Alexza scores $130M pact for agitation therapy
Alexza Pharmaceuticals is scooping up a $40 million upfront payment and stands to earn $90 million in milestones after shaking hands with Biovail on a development pact for its inhaled agitation
Alexza shares sink after drug flunks IIb
Shares of Alexza Pharmaceuticals (ALXA) sank after the developer announced that its migraine therapy failed a Phase IIb trial. "The failure to reach statistical significance on the primary endpoint
